Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of siltuximab versus placebo with best supportive care in transfusion-dependent lower-risk myelodysplastic syndrome
NL-OMON35441Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Siltuximab + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Reduction in red blood cell transfusions. Started Mar 2012; status: active, not recruiting.
02
Drugs
siltuximab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON35441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35441.